Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Castro (St. Louis, United States of America). Dupilumab improves lung function and reduces severe exacerbations in uncontrolled persistent asthma patients with high and low reversibility. 4018

Member's Comments

No comment yet.

Related content which might interest you: Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma Source: ERJ Open Res, 6 (1) 00204-2019; 10.1183/23120541.00204-2019 Year: 2020 Dupilumab improves lung function and reduces severe exacerbations in uncontrolled persistent asthma patients with ongoing allergic rhinitis Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017 Cilomilast decreases exacerbations and maintains lung function in patients with poorly reversible COPD Source: Eur Respir J 2004; 24: Suppl. 48, 88s Year: 2004 Both moderate and severe exacerbations accelerate physical activity decline in COPD patients Source: Eur Respir J, 51 (1) 1702110; 10.1183/13993003.02110-2017 Year: 2018 Does inflammation decrease after recovery from severe exacerbation of COPD? Source: Eur Respir J 2005; 26: Suppl. 49, 53s Year: 2005 Effect of dupilumab on severe exacerbations in asthma patients with and without lung function improvements Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020 Omalizumab treatment reduces asthma exacerbations in children with moderate or severe persistent asthma Source: International Congress 2017 – Paediatric asthma: treatment modalities and behavioural issues Year: 2017 Dupilumab sustains long-term OCS reduction in OCS-dependent asthma patients Source: Virtual Congress 2021 – Asthma and COPD meets COVID-19: new diagnostic tools and results from clinical trials Year: 2021 Predictors of severe exacerbations in patients with moderate and severe asthma Source: International Congress 2018 – Determinants and monitoring of asthma control Year: 2018 Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV1 in patients with severe persistent allergic asthma irrespective of age Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005 Distribution of biomarkers in severe asthma and severe uncontrolled asthma Source: Virtual Congress 2021 – Pearls in asthma and respiratory burden research Year: 2021 Impact of moderate and severe exacerbations in severe COPD patients Source: International Congress 2018 – How far are we in terms of predicting mortality and exacerbations in COPD? Year: 2018 Severe exacerbations predict excess lung function decline in asthma Source: Eur Respir J 2007; 30: 452-456 Year: 2007 Dupilumab improves asthma control and quality of life in children with uncontrolled persistent asthma Source: Virtual Congress 2021 – Paediatric allergic asthma: novel therapeutics and monitoring approaches Year: 2021 The profile of poor ICS adherence in uncontrolled moderate to severe asthma. Source: Virtual Congress 2020 – Advances in asthma treatment Year: 2020 Budesonide/formoterol in a single inhaler acts rapidly to improve lung function and relieve symptoms in patients with moderate to severe COPD Source: Eur Respir J 2002; 20: Suppl. 38, 242s Year: 2002 Tiotropium reduces asthma exacerbations in asthmatic patients with persistent airflow obstruction uncontrolled despite treatment in accordance with guidelines Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma Year: 2012 Tiotropium reduces oral prednisone requirements while improving respiratory function in patients with severe persistent asthma Source: International Congress 2016 – Novel mechanisms and treatment modalities in asthma Year: 2016 A treatment regime based on induced sputum eosinophilia does not result in a reduction in exacerbations in refractory severe asthmatics Source: Annual Congress 2008 - Severe asthma: a heterogeneous clinical entity Year: 2008 Analysis of causes and quality of patients‘ treatment with often severe asthma exacerbations Source: Eur Respir J 2007; 30: Suppl. 51, 72s Year: 2007